ANDA 202553, held by Accord Healthcare. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 202553 (Amlodipine Besylate), held by Accord Healthcare, was first approved by FDA on Apr 29, 2013, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2013 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 10MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Apr 2, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 2, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 29, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters